Investigating the Prevalence and Risk Factors for Sarcopenia Amongst Adults Seeking Treatment for Obesity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Obesity. Basic parameters: 21 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Singapore
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Sarcopenia, a condition where individuals lose muscle mass and strength, is associated with poorer health and function. While aging is a well-known cause of sarcopenia, obesity is increasingly recognised as a significant factor. When sarcopenia and obesity occur together, it can result in more severe health problems. This is especially concerning because weight loss, the treatment for obesity, can further reduce muscle mass and potentially worsen the situation. Despite this, it is unknown how common sarcopenia is among people with obesity, as only a few studies have looked into this using the most accurate diagnostic criteria, showing a prevalence of 4-13%. In this study, the investigators will examine the prevalence of sarcopenia in 300 adults with obesity at a specialized Obesity Center. The investigators expect to find a higher prevalence among Asian participants due to differences in body composition compared to other ethnic groups. The investigators will also explore various factors that might be linked to sarcopenia in these individuals, such as age, gender, race, body mass index, smoking and alcohol use, medical conditions, medications, physical activity, aerobic capacity, and dietary protein intake. Some of these factors could help in identifying those at risk of sarcopenia and could be targeted for future treatments. Currently, screening for sarcopenia is not a standard part of routine obesity care as it requires specialized equipment and trained staff. By determining how common sarcopenia is in people with obesity, this study will help healthcare providers better understand the problem and allocate resources effectively. Identifying factors associated with sarcopenia will also help streamline diagnosis and monitoring for those at risk.
Primary outcome measures
- Sarcopenia [Time frame: Outcome measures will be recorded at baseline only.]
- Handgrip strength [Time frame: Outcome measures will be recorded at baseline only.]
- 5-time chair stand test [Time frame: Outcome measures will be recorded at baseline only.]
- 30-second sit-to-stand test [Time frame: Outcome measures will be recorded at baseline only.]
Secondary outcome measures (3)
- Aerobic capacity [Time frame: At baseline]
- Physical activity questionnaire [Time frame: At baseline]
- Dietary questionnaire [Time frame: At baseline]
Eligibility criteria
Inclusion criteria
- body mass index ≥ 27.5kg/m2
- able to provide informed consent.
Exclusion criteria
- unable to undergo the physical function tests (handgrip strength testing and chair-stand tests)
- pregnant women
- history of bariatric procedures or surgeries
- on medications for treatment of obesity (glucagon-like peptide 1 receptor agonists, phentermine, naltrexone-bupropion, orlistat)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Singapore · 1 center
- Singapore General Hospital — Singapore
Identifiers
NCT: NCT07541677 · sarcopenicobesity